Merck Annual Report 2008 - Sitemap (optimized for printing)

Merck 2008 at a glance
- Achievements of 2008
- Development 1999-2008
- Staying the course
- Business sectors
- Financial calendar
Letter from Karl-Ludwig Kley
Corporate governance and Board
- Corporate governance
  - Merck KGaA
  - Remuneration and ownership of shares
- Report of the Supervisory Board
- Executive Board
  - Dr. Karl-Ludwig Kley
  - Dr. Michael Becker
  - Dr. Bernd Reckmann
  - Elmar Schnee
- Supervisory Board
- Board of Partners of E. Merck KG
Merck shares
- Share price development
- Share data
- Analysts’ estimates
- Shareholder structure
- Information on capital and shares
Management Report
- Overall economic situation
- Financial position and results of operations
  - Earnings development
  - Exceptional items
  - Financial result
  - Regions
  - Business sectors
    - Pharmaceuticals
    - Chemicals
  - Profit after tax
  - Dividend proposal
  - Free cash flow
  - Total assets
  - Capital spending
  - Value added
- Responsibility
  - Employees
  - Community
  - FTSE4Good
  - Environment and safety
- Corporate and Other
- Risk report
  - Business-related risks
  - Financial risks
  - Rating
  - Legal risks
  - Human resource risks
  - Other risks
- Report on expected developments
- Subsequent events
Pharmaceuticals
- Merck Serono
  - Business development
  - Regions
  - Therapeutic areas
    - Oncology
    - Neurodegenerative Diseases
    - Autoimmune and Inflammatory Diseases
    - Fertility
    - Endocrinology
    - CardioMetabolic Care
  - Research and development
    - Overview compounds
    - Cooperations
    - Oncology
    - Neurodegenerative Diseases
    - Fertility
    - Autoimmune and Inflammatory Diseases
    - Endocrinology
- Consumer Health Care
  - Business development
  - Regions
  - Brands
Chemicals
- Liquid Crystals
  - Business development
  - Research and development
- Performance & Life Science Chemicals
  - Business development
  - Regions
  - Laboratory Business
  - Life Science Solutions
  - Pigments
Financial Statements
- Income Statement
- Balance Sheet
- Segment Reporting
  - Business sectors
  - Regions
- Cash Flow Statement
- Free Cash Flow
- Income and Expense
- Changes in Net Equity
Notes
- Acquisitions
- Disposals/Discontinued operations
- Accounting policies
- Notes to the income statement
  - Sales
  - Royalty income
  - Cost of sales
  - Marketing and selling expenses
  - Administration expenses
  - Other operating income and expenses
  - Research and development
  - Amortization of intangible assets
  - Investment result
  - Exceptional items
  - Financial result
  - Income tax
  - Profit after tax from discontinued operations
  - Minority interest
  - Earnings per share
- Notes to the balance sheet
  - Cash and cash equivalents
  - Marketable securities
  - Trade accounts receivable
  - Inventories
  - Other assets
  - Tax receivables
  - Assets/ liabilities held for sale
  - Intangible assets
  - Property, plant and equipment
  - Non-current financial assets
  - Financial liabilities
  - Trade accounts payable
  - Other liabilities
  - Tax liabilities
  - Provisions
  - Provisions for pensions
  - Net equity
- Notes to the segment reporting
- Notes to the cash flow statement
  - Net cash flows from operating activities
  - Net cash flows from investing activities
  - Net cash flows from financing activities
  - Cash and cash equivalents
  - Free cash flow
- Other disclosures
  - Derivative financial instruments
  - Management of financial risks
  - Other disclosures on financial instruments
  - Contingent liabilities
  - Other financial obligations
  - Personnel expenses
  - Material costs
  - Auditors' fees
  - Corporate Governance
  - Companies opting for exemption
  - Related-party disclosures
  - Preparation and approval
- Auditor's Report